Kyushu University · Medicine
Professor Hiroki Hashimoto's research lab focuses on nuclear medicine and molecular imaging, particularly the development and clinical application of novel radiotracers such as (11)C-PBB3 for positron emission tomography (PET) in oncology and neurodegenerative diseases. The lab also investigates molecular mechanisms of stress-activated kinases in fish models to understand conserved signaling pathways relevant to human disease. Additionally, the lab explores the clinical outcomes and treatment responses in rare malignancies like metastatic extramammary Paget’s disease and the histopathological spectrum of immune checkpoint inhibitor-induced skin reactions, especially in Asian populations. These interdisciplinary efforts bridge molecular biology, translational medicine, and clinical oncology to improve diagnostic accuracy and therapeutic strategies.
Figures are computed from collected data and may differ slightly.
(11)C-PBB3 was produced with sufficient radioactivity and high quality, demonstrating its clinical utility. The present results of radiosynthesis, photoisomerization, biodistribution, and metabolite analysis could be helpful for the reliable production and application of (11)C-PBB3 in diverse PET facilities.
Two distinct stress-activated protein kinase (JNKa and b) cDNAs were isolated from a carp ovary cDNA library. These cDNAs contained a full-length open reading frame encoding 427 amino acid residues with a predicted mass of 48.6 kDa. The deduced amino acid sequences of JNKa and b were 95.8% identical, with 18 residues replaced, and showed a high degree of sequence similarity to mammalian JNK/SAPK subgroup including the common dual phosphorylation motif of TPY. By Northern blot analysis, the carp
The efficacy and survival impact of conventional chemotherapies for metastatic extramammary Paget's disease (EMPD) have not been fully elucidated. This study examined the long-term outcome of chemotherapy for this indication. We conducted a retrospective review of 21 patients with distant metastatic EMPD (14 patients treated with chemotherapy and 7 patients treated without chemotherapy). The response rate of chemotherapy and patient survival were statistically analyzed. Among the 14 patients tre
Immune checkpoint inhibitors (ICIs) cause a variety of inflammatory eruptions. The understanding of ICI-induced inflammatory eruptions with detailed histopathological findings is not adequate, particularly in Asian populations. In this study, we retrospectively reviewed 51 patients who were histopathologically diagnosed with cutaneous immune-related adverse events (irAEs) following ICI therapy between 2014 and 2020 at the Department of Dermatology of Kyushu University Hospital. Of the 51 patient
Boundary area tumor involvement was a major risk factor for incomplete excision, local recurrence, and poor survival outcomes. However, incomplete removal of primary tumors was not significantly associated with poor prognosis. A less invasive surgical approach for preserving anogenital and urinary functions may be acceptable as the first-line treatment for resectable EMPD.
Open papers in the app to read, cite, and organize with AI.
